Iron chelating intervention
Phase 3Small molecule
Iron chelating intervention is one of 52 small molecule programs targeting Friedreich ataxia. It is currently in Phase 3.
2
Indications
2
Total Trials
1
Active Trials
51
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
44 competitors in Beta-Thalassemia
#DrugCompanyPhaseTrials
1Exjade
NovartisApproved
Thalomid
Bristol-Myers SquibbApproved
Droxia
TTheravia
Approved
Desferal
Alnylam PharmaceuticalsApproved
Glucophage
EMD SeronoApproved
Viagra
VViatris Specialty LLC
Approved
Vidaza
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Ferriprox
Chiesi Farmaceutici S.p.A.Approved
Aqvesme
AAgios Pharmaceuticals, Inc.
Phase 3
Alpha Lipoic Acid
NNational Center for Complementary and Integrative Health (NCCIH)
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Iron chelating intervention. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- TTanta University